New Strong Sell Stocks for April 13th

Lazard, Ares Management, and AkzoNobel were added to the Zacks Rank #5 (Strong Sell) list after their current-year earnings estimates were cut by 4.6%, 4.1%, and nearly 4%, respectively, over the last 60 days. The update signals deteriorating analyst expectations and weaker fundamental sentiment for all three names. The article is largely a stock-screening note and is unlikely to have broad market impact.

Analysis

The immediate market signal is not the downgrades themselves; it is that both names sit in fee-sensitive, equity-market-linked businesses where estimate cuts often lag the real operating slowdown. For Lazard, a softer advisory pipeline can quickly become a compounding problem because deferred M&A and restructuring fees are highly cyclical and operating leverage works in reverse; a modest revenue miss can translate into a much larger EPS miss over the next 1-2 quarters. For Ares, the risk is less about current asset marks and more about future fundraising power: when public-market volatility and credit dispersion rise, LPs become more selective, and the fee base can decelerate before headline AUM growth visibly rolls over.

Second-order, this is a positioning/flow issue as much as a fundamentals issue. Consensus downgrades tend to invite systematic de-rating in high-multiple asset managers, especially if they have been crowded “quality compounder” longs; that can compress valuation faster than underlying fundamentals deteriorate. Ares is more insulated than Lazard because private credit still benefits from bank retrenchment, but if spreads stay tight and deal activity remains subdued, originations can shift from a story of net inflows to one of lower transaction-based monetization.

The contrarian angle is that the selloff may be most attractive only after the market prices in an earnings reset, not on the first round of estimate cuts. If rates remain elevated but stable, these businesses can look worse on sentiment than on cash generation, and any M&A reopening or renewed LBO activity can produce a sharp upside surprise in advisory revenue and fee-related earnings. The key reversal catalyst is not macro growth alone; it is a pickup in transaction velocity and refinancing volume, which would matter more than modest changes in AUM.

Key Decisions for Investors

• Short LAZ into strength over the next 2-6 weeks; target a 1.5-2.0 turn forward P/E de-rating if advisory activity stays weak, with a stop if announced deal volume materially re-accelerates.
• Pair trade: long ARES / short LAZ for 1-3 months; ARES should better absorb a soft fee environment due to stickier recurring earnings, while LAZ has higher downside convexity to delayed capital markets activity.
• Buy LAZ put spreads 1-2 quarters out to express downside to earnings revisions with defined risk; best if implied volatility remains below realized volatility after the downgrade cycle begins.
• For ARES, avoid chasing downside unless spreads widen or fundraising commentary deteriorates; use any broad risk-off tape to initiate shorts only if credit originations and fee-related earnings estimates roll over together.
• If transaction volumes improve, cover LAZ shorts quickly and rotate into ARES on pullbacks; the rebound trade is likely to be sharper in the higher-quality recurring-fee platform.